Orexigen Therapeutics, Inc.  

(Public, NASDAQ:OREX)   Watch this stock  
Find more results for OREX
-0.14 (-5.53%)
After Hours: 2.43 +0.04 (1.67%)
Oct 13, 7:36PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.39 - 2.57
52 week 1.84 - 9.37
Open 2.50
Vol / Avg. 2.80M/3.59M
Mkt cap 299.69M
P/E     -
Div/yield     -
EPS -0.23
Shares 125.39M
Beta 2.29
Inst. own 101%
Nov 9, 2015
Q3 2015 Orexigen Therapeutics Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Sep 10, 2015
Orexigen Therapeutics Inc at Wells Fargo Healthcare Conference
Aug 6, 2015
Q2 2015 Orexigen Therapeutics Inc Earnings Release
Aug 6, 2015
Q2 2015 Orexigen Therapeutics Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -433.27% -67.59%
Operating margin -399.08% -54.99%
EBITD margin - -54.74%
Return on average assets -46.39% -19.09%
Return on average equity -2249.55% -116.89%
Employees 47 -
CDP Score - -


3344 N Torrey Pines Ct Ste 200
LA JOLLA, CA 92037-1024
United States - Map
+1-858-8758600 (Phone)
+1-858-8758650 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Orexigen Therapeutics, Inc. (Orexigen) is a biopharmaceutical company. The Company is focused on the development of pharmaceutical product candidates for the treatment of obesity. The Company's product is Contrave, a fixed dose combination of bupropion hydrochloride (HCl) extended release (ER) and naltrexone HCl ER. The Company's product Contrave, is approved in the United States by the United States Food and Drug Administration (FDA) as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI), of around 30 kilograms per square meter (kg/m2) or greater (obese), or around 27 kilograms per square meter or greater (overweight) in the presence of at least one weight-related comorbid condition. The Company also submitted an application for marketing authorization with the European Medicines Agency (EMA) for Contrave under the name Mysimba.

Officers and directors

Eckard Weber M.D. Independent Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Michael A. Narachi President, Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
Joseph P. Hagan Acting Chief Financial Officer, Treasurer, Chief Business Officer
Age: 46
Bio & Compensation  - Reuters
Thomas Cannell Executive Vice President, Chief Commercial Officer
Age: 53
Bio & Compensation  - Reuters
Preston S. Klassen M.D. Senior Vice President, Head of Global Development
Age: 46
Bio & Compensation  - Reuters
Chris Hazuka Acting General Counsel
Bio & Compensation  - Reuters
Louis C. Bock Independent Director
Age: 50
Bio & Compensation  - Reuters
Wendy L. Dixon Ph.D. Independent Director
Age: 59
Bio & Compensation  - Reuters
Brian H. Dovey Independent Director
Age: 73
Bio & Compensation  - Reuters
David J. Endicott Independent Director
Age: 50
Bio & Compensation  - Reuters